2013-2014

This page in English

2014

Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center.
Lourdudoss C, Vollenhoven R
Lupus 2014 Mar;23(3):299-304

Editorial.
Buyon J, van Vollenhoven R
Lupus Sci Med 2014 ;1(1):e000028

Lupus Science and Medicine: the Editors present highlights for the bedside and for the bench in the inaugural issue.
Buyon J, van Vollenhoven R
Lupus Sci Med 2014 ;1(1):e000033

Diagnostic utility of musculoskeletal ultrasound in patients with suspected arthritis--a probabilistic approach.
Rezaei H, Torp-Pedersen S, af Klint E, Backheden M, Kisten Y, Györi N, et al
Arthritis Res. Ther. 2014 Oct;16(5):448

Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N, den Broeder A, Jacobs W, van der Maas A, Bijlsma J, van Vollenhoven R, et al
Cochrane Database Syst Rev 2014 Sep;(9):CD010455

Tofacitinib versus methotrexate in rheumatoid arthritis.
Wilkinson B, Krishnaswami S, van Vollenhoven R
N. Engl. J. Med. 2014 Sep;371(12):1164-5

Response to: 'MBDA: what is it good for?' by Yazici et al.
van Vollenhoven R, Hambardzumyan K, Chernoff D, Bolce R
Ann. Rheum. Dis. 2014 Nov;73(11):e73

Rituximab and lupus--a promising pair?
Ekö S, van Vollenhoven R
Curr Rheumatol Rep 2014 ;16(9):444

Tofacitinib versus methotrexate in rheumatoid arthritis.
Lee E, Fleischmann R, Hall S, Wilkinson B, Bradley J, Gruben D, et al
N. Engl. J. Med. 2014 Jun;370(25):2377-86

Advances in the treatment of rheumatoid arthritis.
Vivar N, Van Vollenhoven R
F1000Prime Rep 2014 ;6():31

Dose reduction of tocilizumab in rheumatoid arthritis patients with low disease activity.
van Herwaarden N, Herfkens-Hol S, van der Maas A, van den Bemt B, van Vollenhoven R, Bijlsma J, et al
Clin. Exp. Rheumatol. ;32(3):390-4

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
van Vollenhoven R, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al
Ann. Rheum. Dis. 2014 Jun;73(6):958-67

American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort.
Urowitz M, Gladman D, Ibañez D, Sanchez-Guerrero J, Romero-Diaz J, Gordon C, et al
J. Rheumatol. 2014 May;41(5):875-80

Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study.
Askling H, Rombo L, van Vollenhoven R, Hallén I, Thörner , Nordin M, et al
Travel Med Infect Dis ;12(2):134-42

The early clinical course of infliximab treatment in rheumatoid arthritis: results from the REMARK observational study.
Westhovens R, van Vollenhoven R, Boumpas D, Brzosko M, Svensson K, Bjorneboe O, et al
Clin. Exp. Rheumatol. ;32(3):315-23

Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply.
Petri M, van Vollenhoven R, Buyon J, Levy R, Navarra S, Cervera R, et al
2014 Feb;66(2):480

Early start and stop of biologics: has the time come?
van Vollenhoven R, Nagy G, Tak P
BMC Med 2014 Feb;12():25

Changes in quality of life in the first 5 years of disease in a multicenter cohort of patients with systemic lupus erythematosus.
Urowitz M, Gladman D, Ibañez D, Sanchez-Guerrero J, Bae S, Gordon C, et al
Arthritis Care Res (Hoboken) 2014 Sep;66(9):1374-9

25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort.
Lertratanakul A, Wu P, Dyer A, Urowitz M, Gladman D, Fortin P, et al
Arthritis Care Res (Hoboken) 2014 Aug;66(8):1167-76

Peripheral and site-specific CD4(+) CD28(null) T cells from rheumatoid arthritis patients show distinct characteristics.
Pieper J, Johansson S, Snir O, Linton L, Rieck M, Buckner J, et al
Scand. J. Immunol. 2014 Feb;79(2):149-55

New drugs in systemic lupus erythematosus: when to start and when to stop.
Mosca M, van Vollenhoven R
Clin. Exp. Rheumatol. ;31(4 Suppl 78):S82-5

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.
Smolen J, Emery P, Fleischmann R, van Vollenhoven R, Pavelka K, Durez P, et al
Lancet 2014 Jan;383(9914):321-32

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
Keystone E, Landewé R, van Vollenhoven R, Combe B, Strand V, Mease P, et al
Ann. Rheum. Dis. 2014 Dec;73(12):2094-100

2013

Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study.
Hanly J, Urowitz M, O'Keeffe A, Gordon C, Bae S, Sanchez-Guerrero J, et al
Arthritis Rheum. 2013 Nov;65(11):2887-97

Biologics in SLE: towards new approaches.
van Vollenhoven R, Parodis I, Levitsky A
Best Pract Res Clin Rheumatol 2013 Jun;27(3):341-9

Perspectives in biological physics: the nDDB project for a neutron Dynamics Data Bank for biological macromolecules.
Rusevich L, García Sakai V, Franzetti B, Johnson M, Natali F, Pellegrini E, et al
Eur Phys J E Soft Matter 2013 Jul;36(7):80

Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports.
Bexelius C, Wachtmeister K, Skare P, Jönsson L, Vollenhoven R
Lupus 2013 Jul;22(8):793-801

Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study.
den Broeder A, van Herwaarden N, van der Maas A, van den Hoogen F, Bijlsma J, van Vollenhoven R, et al
BMC Musculoskelet Disord 2013 Oct;14():299

Case 16-2013: A girl with irritability, hypersomnia, and somatic symptoms.
van Vollenhoven R
N. Engl. J. Med. 2013 Sep;369(12):1174

Health-related quality of life, fatigue and mood in patients with SLE and high levels of pain compared to controls and patients with low levels of pain.
Waldheim E, Elkan A, Pettersson S, van Vollenhoven R, Bergman S, Frostegård J, et al
Lupus 2013 Oct;22(11):1118-27

Challenges and opportunities in SLE clinical trials.
van Vollenhoven R
Curr Opin Rheumatol 2013 Sep;25(5):606-15

Rheumatoid arthritis. Triple therapy or etanercept after methotrexate failure in RA?
van Vollenhoven R, Chatzidionysiou K
Nat Rev Rheumatol 2013 Sep;9(9):510-2

Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
Szepietowski J, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven R, et al
Arthritis Rheum. 2013 Oct;65(10):2661-71

Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial.
Eriksson J, Neovius M, Bratt J, Petersson I, van Vollenhoven R, Geborek P, et al
JAMA Intern Med 2013 Aug;173(15):1407-14

Limitations of current treatments for systemic lupus erythematosus: a patient and physician survey.
Strand V, Galateanu C, Pushparajah D, Nikaï E, Sayers J, Wood R, et al
Lupus 2013 Jul;22(8):819-26

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri M, van Vollenhoven R, Buyon J, Levy R, Navarra S, Cervera R, et al
Arthritis Rheum. 2013 Aug;65(8):2143-53

Novel targeted therapies: the future of rheumatoid arthritis? Mavrilumab and tabalumab as examples.
Combe B, van Vollenhoven R
Ann. Rheum. Dis. 2013 Sep;72(9):1433-5

Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden.
Raaschou P, Simard J, Holmqvist M, Askling J,
BMJ 2013 Apr;346():f1939

B-cell-directed therapies in systemic lupus erythematosus--where do we stand?
van Vollenhoven R
Lupus 2013 Apr;22(4):341

The comparison of trial data-based and registry data-based cost-effectiveness of infliximab treatment for rheumatoid arthritis in Sweden using a modeling approach.
Lekander I, Kobelt G, Svarvar P, Ljung T, van Vollenhoven R, Borgström F
Value Health ;16(2):251-8

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.
Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al
Lancet 2013 May;381(9877):1541-50

Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial.
Rezaei H, Saevarsdottir S, Geborek P, Petersson I, van Vollenhoven R, Forslind K
BMC Musculoskelet Disord 2013 Mar;14():79

Small molecular compounds in development for rheumatoid arthritis.
van Vollenhoven R
Curr Opin Rheumatol 2013 May;25(3):391-7

Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.
Genovese M, Rubbert-Roth A, Smolen J, Kremer J, Khraishi M, Gómez-Reino J, et al
J. Rheumatol. 2013 Jun;40(6):768-80

Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy.
van Vollenhoven R
Nat Rev Rheumatol 2013 Feb;9(2):70-2

Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response.
Jónsdóttir T, Zickert A, Sundelin B, Henriksson E, van Vollenhoven R, Gunnarsson I
Rheumatology (Oxford) 2013 May;52(5):847-55

Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort.
Chatzidionysiou K, van Vollenhoven R
Scand. J. Rheumatol. 2013 ;42(3):190-5

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.
Wallace D, Navarra S, Petri M, Gallacher A, Thomas M, Furie R, et al
Lupus 2013 Feb;22(2):144-54

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
Karlsson J, Neovius M, Nilsson J, Petersson I, Bratt J, van Vollenhoven R, et al
Ann. Rheum. Dis. 2013 Dec;72(12):1927-33

Extent and characteristics of self-reported pain in patients with systemic lupus erythematosus.
Waldheim E, Elkan A, Bergman S, Frostegård J, van Vollenhoven R, Henriksson E
Lupus 2013 Feb;22(2):136-43

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.
van Vollenhoven R, Emery P, Bingham C, Keystone E, Fleischmann R, Furst D, et al
Ann. Rheum. Dis. 2013 Sep;72(9):1496-502

The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice.
Lekander I, Borgström F, Lysholm J, van Vollenhoven R, Lindblad S, Geborek P, et al
Eur J Health Econ 2013 Dec;14(6):863-73

Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.
Parker B, Urowitz M, Gladman D, Lunt M, Bae S, Sanchez-Guerrero J, et al
Ann. Rheum. Dis. 2013 Aug;72(8):1308-14

Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate.
Smolen J, van der Heijde D, Keystone E, van Vollenhoven R, Goldring M, Guérette B, et al
Ann. Rheum. Dis. 2013 Jul;72(7):1156-62

Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports.
Bexelius C, Wachtmeister K, Skare P, Jönsson L, Vollenhoven R
Lupus 2013 Jul;22(8):793-801

InflammationReumatologi